Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03717558Phase 1Withdrawn

Bioavailability Pilot Study of Versus W0035 Versus Stromectol

Role: lead

NCT01056341Phase 2Completed

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

Role: lead

NCT01512173Phase 2Completed

Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo

Role: lead

NCT01861626Phase 1Completed

Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects

Role: lead

All 4 trials loaded